CD274 and neoplasm: Importantly, this study highlights the emerging role of predictive biomarkers—including tumor mutational burden, interferon signaling defects, CD8+ T cell infiltration, PD-L1 expression, and gut microbiota composition—in influencing response to OV therapy.